OneMedNet Completes Securities Purchase Agreement, Solidifying Cash Position to Accelerate Growth

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
OneMedNet secures a significant cash infusion of up to $4.54 million through a private placement of senior convertible notes, aiming to bolster its Real World Data platform and accelerate growth.
  • None.
  • None.

OneMedNet's recent capital raise through a private placement of senior convertible notes is a strategic move to enhance liquidity and support operational expansion. The $4.54 million in funding is significant for a company of OneMedNet's scale, potentially extending its cash runway and providing resources for working capital. Convertible notes are a debt instrument that can be converted into equity, often at a discount to the future equity pricing round. This mechanism can be attractive to investors seeking both the security of debt and the upside potential of equity.

The choice of this financial instrument may reflect the company's confidence in its future valuation, as well as a willingness to manage dilution in a way that aligns with growth prospects. For stakeholders, the immediate benefit is the infusion of cash without immediate dilution, while the long-term impact hinges on the company's performance and the terms of conversion, which could affect share price and ownership structure.

The investment into OneMedNet's iRWD™ platform indicates a growing market interest in Real World Data solutions, particularly in high-stakes areas such as oncology and cardiology. Real World Data is becoming increasingly valuable for pharmaceutical companies, regulatory bodies and healthcare providers, as it can inform clinical trial designs, support regulatory submissions and guide personalized treatment decisions.

OneMedNet's positioning in this market, coupled with the fresh capital, suggests potential for increased market share and competitive advantage. However, the company's ability to capitalize on this investment will depend on its execution capabilities and the effectiveness of its AI-driven solutions in delivering meaningful insights. As healthcare continues to evolve towards data-driven decision-making, OneMedNet's role could become more central, impacting patient outcomes and healthcare innovation.

The involvement of multiple advisors and legal counsels in the transaction underscores the complexity and importance of compliance in securities offerings. The distinction made in the press release regarding the sale of securities only in jurisdictions where it is lawful reflects the intricate regulatory landscape governing private placements. It is imperative for investors to understand that such financial instruments are subject to regulatory scrutiny and may carry risks associated with the legal framework.

For OneMedNet, adherence to securities laws and regulations is important in maintaining investor confidence and avoiding potential legal challenges. The collaboration with seasoned legal advisors indicates the company's commitment to due diligence and may instill a sense of trust among potential investors. Nevertheless, the actual terms of the notes, including conversion rates and triggers, will be pivotal in determining the legal and financial implications for both the company and the note holders.

Cash Infusion Provides Significant Cash Runway of Up to $4.54 Million

MINNEAPOLIS, April 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (“iRWD™”), through its proven OneMedNet iRWD™ solution, today announced that it has entered into a definitive securities purchase agreement (the “Securities Purchase Agreement“) dated as of March 28, 2024 with an institutional investor (the “Investor“) providing up to $4.54 million in funding through a private placement for the issuance of senior convertible notes (the “Notes”). OneMedNet intends to use the net proceeds when received from the offering for working capital purposes.

“This Securities Purchase Agreement demonstrates confidence in our comprehensive iRWD™ platform, marking an important milestone for OneMedNet as we have the investment needed to expedite our growth, enhance our network, and propel the development of our AI-driven solutions. Our platform is designed to meet the clinical requirements necessary across various domains, including but not limited to rare diseases, oncology, and cardiology. We are committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of our strategy to enhance patient outcomes and pave the next wave of healthcare innovation," said Aaron Green, President & CEO of OneMedNet.


EF Hutton LLC acted as the placement agent in the offering. ARC Group Ltd. acted as financial advisor and capital markets advisor to OneMedNet Corporation.

Rimon P.C. acted as legal counsel to OneMedNet Corporation on the Notes Offering and Lucosky Brookman LLP acted as legal counsel to the Investor.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale, would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About OneMedNet Corporation

Founded in 2009, OneMedNet provides innovative solutions that unlock the significant value contained within the clinical data repositories of healthcare providers. OneMedNet's robust iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records (EHR), laboratory results, medical imaging data. Employing its proven OneMedNet iRWD™ platform, OneMedNet securely de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to healthcare providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science requirements. Our commitment to leveraging real-world data translates into healthcare innovations, setting new standards in patient care and advancing the future of medicine. For more information, please visit

Safe Harbor Statement

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Investor Contact:

Shannon Devine / Rory Rumore
MZ Group North America

Company Contact:

OneMedNet Corporation
Michael Wong, Director of Marketing
Phone: 800.918.7189

Source: OneMedNet 


What is the amount of cash infusion secured by OneMedNet ?

OneMedNet secured up to $4.54 million through a private placement of senior convertible notes.

What is the purpose of the net proceeds from the offering?

The net proceeds from the offering will be utilized for working capital purposes by OneMedNet

Who acted as the placement agent in the offering?

EF Hutton acted as the placement agent in the offering for OneMedNet

Who is the President & CEO of OneMedNet?

Aaron Green serves as the President & CEO of OneMedNet

What is the focus area of OneMedNet's platform?

OneMedNet's platform is designed to meet clinical requirements across various domains, including rare diseases, oncology, and cardiology.

OneMedNet Corporation


ONMD Rankings

ONMD Latest News

ONMD Stock Data

Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
United States of America